End-of-Phase 1 Meeting with FDA and Receipt of Fast Track Designation for LYT-200 in R/R High-Risk MDS Announced
“Our productive End-of-Phase 1 meeting with the U.S. FDA provides a clear path to advance LYT-200 into Phase 2 development,” said Eric Elenko, PhD, Acting Chief Executive Officer of Gallop Oncology and Co-founder of PureTech. “The STRIDE-MDS trial will seek to confirm the unprecedented clinical activity observed in Phase 1b, while its randomized, double-blind design will enable a clear assessment of the contribution of effect of LYT-200. Additionally, the inclusion of two doses is intended to fulfill the dose-selection requirements in accordance with FDA’s Project Optimus. With its mutation-agnostic approach and potential to benefit a broad range of patients, LYT-200 could represent an important new treatment option for R/R HR- MDS.”
Share:
More News
Akeso, Inc. announced that AK158D1, its investigational next-generation bispecific antibody-drug conjugate (ADC) targeting EGFR and TROP2, has secured Phase I clinical trial clearance from the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration (NMPA). The trial will assess the candidate in patients with advanced malignant solid tumors.
“This financing marks a significant milestone as we execute upon our vision of harnessing the power of macrocycles to transform the treatment of cancer,” said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma. “Momentum around our cyclin D1 program has continued to build as CID-165
“FDA Fast Track designation for KST-6051 is an important regulatory milestone for Kestrel, based on the strength of our preclinical data package. This designation will allow us to work more closely with the FDA as we advance KST-6051 through our ongoing Phase 1 study, with the goal of bringing a
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “Today’s deal secures a promising T cell engager and advances GSK’s leadership goals in blood cancer. The agreement complements our existing portfolio in multiple myeloma, adding a new potential option to address the different needs of patients facing this